J. Douketis and J. Julian, Kearon C Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study

O. Gagneur, Contraception difficile www.insitu.fr consulté le 14

H. Geoffrey, et coll Efficacy and safety of a transdermal contraceptive system, Am.J.Obstet.Gynecol, vol.98, issue.5, pp.799-805, 2001.

J. Gris, C. Jamin, and J. Renifla, APC resistance and third-generation oral contraceptives: Acquired resistance to activated protein C, oral contraceptives and the risk of thromboembolic disease, Human Reproduction, vol.16, issue.1, pp.3-8, 2001.
DOI : 10.1093/humrep/16.1.3

L. Heinemann and J. Dinger, Safety of a new oral contraceptive containing drospirénone Drug Saf2004, pp.1001-1019

. Huberj, Clinical experience with a new norgestimate containing oral contraceptive !nt J, Fertil, vol.suppl, issue.1, pp.47-53, 1992.

J. Kemmeren, A. Algra, J. Meijers, and B. Bouma, Grobbee DE Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation

C. Klerft, Importance of levonorgestrel dose in oral contraception for effects on coagulation Lancet; 4; 354, pp.832-833, 1999.

J. Kujovich, Hormones and pregnancy: thromboembolic risks for women, British Journal of Haematology, vol.57, issue.4, pp.443-454, 2004.
DOI : 10.1002/(SICI)1097-0142(19970515)79:10<2024::AID-CNCR25>3.0.CO;2-V

C. Legnoni and . Venous-thromboembolism, Venous thromboembolism, oral contraceptives and high prothrombin levels, Journal of Thrombosis and Haemostasis, vol.96, issue.1, pp.112-117, 2003.
DOI : 10.1046/j.1538-7836.2003.00008.x

J. Lercef, Nutrition à la ménopause www.menopauseafem.com consulté le 18

J. Lidegaard and B. Edstrom, Oral contraceptives and venous thromboembolism: a five-year national case-control study???, Contraception, vol.65, issue.3, pp.187-196, 2002.
DOI : 10.1016/S0010-7824(01)00307-9

S. Un and . Le-raloxifène, Evista®),dans la prévention et le traitement de l'ostéoporose post- ménopausique www

. Nouveaux-traitements-de-la-ménopause, SERM, tibolone, phytoestrogenes) et risques cardiovasculaires http, p.6

H. Refn, Metabolic changes during treatment with two different progestogens, American Journal of Obstetrics and Gynecology, vol.163, issue.1, pp.374-377, 1990.
DOI : 10.1016/0002-9378(90)90585-U

J. Schering and V. Pungier, La contraception hormonale Le Moniteur des pharmacies et des laboratoire, pp.5-15, 2004.

J. Sidemann, J. Jespersen, and L. Andersen, Skouby SO Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climateric Study

M. Smirnov, . Safa-0, and N. Esmon, Esmon CT Inhibition of activated protein C Anticoagulant activity by prothrombin Blood, ·, vol.94, pp.3839-3846, 1999.

N. Smith and S. Heckbert, Esterified Estrogens and Conjugated Equine Estrogens and the Risk of Venous Thrombosis, JAMA, vol.292, issue.13, pp.1581-1588, 2004.
DOI : 10.1001/jama.292.13.1581

P. Tanis and F. Rosendaal, Thrombosis during oral contraceptive use Sem Vase Med, pp.70-83, 2003.

A. Tripodi, V. Chantarangkul, and P. Manuccio, Hyperprothrombinemia may result in acquired activated protein C resistance, Blood, vol.96, issue.9, pp.3295-3296, 2000.

V. Vilet and H. , Association between sex hormone binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing differents progestogens, Hum Reprod, vol.20, issue.2, pp.563-568, 2005.